Loading...

Ascletis Pharma Inc.

ASCLFPNK
Healthcare
Biotechnology
$1.90
$0.00(0.00%)

Ascletis Pharma Inc. (ASCLF) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Ascletis Pharma Inc. (ASCLF), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-97.73%
97.73%
Operating Income Growth
-31.48%
31.48%
Net Income Growth
-107.95%
107.95%
Operating Cash Flow Growth
-136.94%
136.94%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-6.18%
6.18%
ROIC
-8.81%
8.81%

Ascletis Pharma Inc. (ASCLF) Income Statement & Financial Overview

View the income breakdown for Ascletis Pharma Inc. ASCLF across both annual and quarterly reports.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$641500.00$641500.00$0.00$0.00
Cost of Revenue$274000.00$274000.00$0.00$0.00
Gross Profit$367500.00$367500.00$0.00$0.00
Gross Profit Ratio$0.57$0.57$0.00$0.00
R&D Expenses$85.006M$85.006M$66.19M$66.19M
SG&A Expenses$30.19M$30.19M$20.68M$20.68M
Operating Expenses$115.20M$115.20M$86.87M$86.87M
Total Costs & Expenses$115.47M$115.47M$86.87M$86.87M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$3.51M$4.01M$4.01M$4.01M
EBITDA-$111.83M-$111.34M-$82.96M-$82.96M
EBITDA Ratio-$174.33-$173.55$0.00$0.00
Operating Income-$114.83M-$114.83M-$86.87M-$86.87M
Operating Income Ratio-$179.006-$179.006$0.00$0.00
Other Income/Expenses (Net)$29.52M$29.52M$21.71M$21.71M
Income Before Tax-$85.31M-$85.31M-$65.16M-$65.16M
Income Before Tax Ratio-$132.98-$132.98$0.00$0.00
Income Tax Expense$0.00$0.00$0.00-$99500.00
Net Income-$85.31M-$85.31M-$65.16M-$65.16M
Net Income Ratio-$132.98-$132.98$0.00$0.00
EPS-$0.09-$0.09-$0.06-$0.06
Diluted EPS-$0.09-$0.09-$0.06-$0.06
Weighted Avg Shares Outstanding$986.77M$986.77M$1.02B$1.02B
Weighted Avg Shares Outstanding (Diluted)$986.77M$986.77M$1.02B$1.02B

Over the last four quarters, Ascletis Pharma Inc. achieved steady financial progress, growing revenue from $0.00 in Q1 2024 to $641500.00 in Q4 2024. Gross profit stayed firm with margins at 57% in Q4 2024 versus N/A in Q1 2024. Operating income totaled -$114.83M in Q4 2024, maintaining a -17901% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$111.83M. Net income rose to -$85.31M, with EPS at -$0.09. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;